Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05378698
Other study ID # TRALIS/TRALO-2260
Secondary ID
Status Not yet recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date June 2022
Est. completion date June 2025

Study information

Verified date May 2022
Source University of Zurich
Contact Peter Schmid-Grendelmeier, Prof,MD
Phone +41442553079
Email peter.schmid@usz.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The clinical efficacy of tralokinumab has been demonstrated in the treatment of AD; its MOA however remains insufficiently understood. A better understanding of the mechanisms underlying the clinical effects of tralokinumab would be of great clinical benefit since it may ultimately help us to identify more precisely candidate patients who may benefit from a therapy with tralokinumab.


Description:

Primary objective: To detect and quantify Tralokinumab in the skin of treated AD patients and concurrently characterize the cellular and molecular changes of the cutaneous and systemic immune response Secondary objectives: - Clinical response analysed by SCORAD, IG, DLQI and worst daily pruritus NRS - To identify immunologic changes on a cellular and molecular level in the skin and in the blood in correlation with Tralokinumab levels over the treatment course. - Changes in the skin barrier function over the treatment course Primary outcome: Detection of Tralokinumab in lesional skin after 16 weeks of treatment in comparison to the begin of the study assessed by mass spectrometry with Parallel Reaction Monitoring (PRM) using the Orbitrap ECLIPSE mass spectrometer Secondary outcome: - Clinical response analysed by SCORAD, IG, DLQI and worst daily pruritus NRS - Detection and quantification of Tralokinumab levels in skin biopsies and skin swabs using mass spectrometer-based proteomics. - Immunologic changes on a cellular and molecular level in the skin (assessed by IMC and mass spectrometer-based proteomics) and in the blood (OLINK targeted proteomics) in correlation with Tralokinumab levels over the treatment course. - Changes in skin impedance (as a parameter for barrier changes) measured by NeviSense - Levels of free IL-13 in blood serum and in skin biopsies - Levels of serum IgE (total, specific) - Blood eosinophil counts


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 25
Est. completion date June 2025
Est. primary completion date December 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Inclusion criteria (patients): - Moderate to severe AD - EASI < 50 - 18-65 years old - Subject is capable of giving informed consent - Signed informed consent Inclusion criteria (Healthy controls): - No diagnosis or history of atopic dermatitis - 18-65 years old - Subject is capable of giving informed consent - Signed informed consent Exclusion Criteria: - Use of systemic corticosteroids or systemic immunosuppressive/immunomodulating drugs within four weeks prior to start of the study - Use of tanning beds or phototherapy within 6 weeks prior to start of the study - History of cancer except for treated basal cell or spinal cell carcinoma of the skin - Active or recurrent bacterial, fungal or viral infection at the time of enrollment, including patients with evidence of Human Immunodeficiency Virus (HIV) infection, Hepatitis B and Hepatitis C infection, active or untreated latent tuberculosis. - Female patients of childbearing potential who are pregnant or breast feeding or planning a pregnancy during the duration of the trial and/or not practicing acceptable birth control for the duration of the trial - Known or suspected non-compliance, drug or alcohol abuse, - Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant, - Previous enrolment into the current study, - Enrolment of the investigator, his/her family members, employees and other dependent persons

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Application of Tralokinumab
2 Arms 20 patients 5 healthy controls

Locations

Country Name City State
Switzerland Allergy Unit, Dept. of Dermatology, Unviersity Hosptial of Zurich Zürich

Sponsors (2)

Lead Sponsor Collaborator
University of Zurich Hochgebirgsklinik Davos-Wolfgang

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Concentration of Tralokinumab in lesional skin after 16 weeks of treatment Concentration of Tralokinumab in lesional skin after 16 weeks of treatment in comparison to the begin of the study assessed by mass spectrometry with Parallel Reaction Monitoring (PRM) using the Orbitrap ECLIPSE mass spectrometer 2 years
Secondary Clinical outcome analysed by SCORAD Clinical response analysed by SCORAD (SCORing Atopic Dermatitis, 0-103, higher scores worse outcome) 2 years
Secondary Clinical outcome analysed by IGA Clinical response analysed by IGA (Investigator Global Assessment, 0-4, higher scores worse outcome) 2 years
Secondary Clinical outcome analysed by DLQI Clinical response analysed by DLQI (Dermatology Life Quality Index, 0-30, higher scores wose outcome 2 years
Secondary Clinical outcome analysed by worst daily pruritus NRS Clinical response analysed by worst daily pruritus NRS Numerating Rating Scale, 0-10, higher values worse outcome) 2 years
Secondary Detection and quantification of Tralokinumab levels in skin biopsies Detection and quantification of Tralokinumab levels in skin biopsies using mass spectrometer-based proteomics 2 years
Secondary Detection and quantification of Tralokinumab levels in skin swabs Detection and quantification of Tralokinumab levels in skin swabs using mass spectrometer-based proteomics. 2 years
Secondary Immunologic changes on a cellular level in the skin Immunologic changes on a cellular level in the skin (assessed by IMC and mass spectrometer-based proteomics) in correlation with Tralokinumab levels over the treatment course 2.5 years
Secondary Immunologic changes on a molecular level in the skin Immunologic changes on molecular level in the skin (assessed by IMC and mass spectrometer-based proteomics) in correlation with Tralokinumab levels over the treatment course. 2.5 years
Secondary Immunologic changes on a cellular and molecular level in the blood Immunologic changes on a cellular level in the blood (OLINK targeted proteomics) in correlation with Tralokinumab levels over the treatment course. 2.5 years
Secondary Immunologic changes on a molecular level in the blood Immunologic changes on a molecular level in the blood (OLINK targeted proteomics) in correlation with Tralokinumab levels over the treatment course. 2.5 years
Secondary Changes in skin impendance asessed by NeviSense Changes in skin impedance (as per parameter for barrier changes) 2.5 years
Secondary Levels of IL-13 in blood serum Levels of IL-13 in blood serum 2.5 years
Secondary Levels of IL-13 in skin biopsies Levels of IL-13 in skin biopsies 2.5 years
Secondary Blood eosinophil counts Eosinophil counts in peripheral blood; normal < 0.4 g/l 2 years
Secondary Levels of total serum IgE Levels of total serum IgE (kU/l) 2 years
See also
  Status Clinical Trial Phase
Completed NCT05018806 - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Terminated NCT03847389 - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Phase 1/Phase 2
Completed NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Phase 1
Active, not recruiting NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Phase 2
Completed NCT05530707 - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Recruiting NCT05509023 - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2
Recruiting NCT05048056 - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04598269 - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2
Recruiting NCT03936335 - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05029895 - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Completed NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Recruiting NCT06366932 - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Phase 4
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2